Top Stories
-
Established two decades ago, the essential tremor brain bank at Columbia has been instrumental in revealing the source and biology of a common but understudied neurodegenerative disorder.
Topic
-
Variants of the ABCA7 gene accelerate neurodegeneration by reducing the amount of neuropeptide Y, a protein essential for maintaining brain synapses.
Topic
-
Analysis of 1.6 million brain cells from older adults has captured the cellular changes that occur in Alzheimer’s early stages, revealing potential new targets and routes for prevention.
Topic
-
An international study shows as many as one-quarter of unresponsive patients with brain injuries have some level of awareness, a finding that could spur development of new treatments.
Topic
Latest News
- May 23, 2022
A transient ischemic attack (TIA) is a stroke that usually lasts under five minutes and resolves on its own, but just because the symptoms disappear, does not mean a TIA should be ignored.
- May 10, 2022
A new initiative led by Columbia University and the n-Lorem Foundation will develop personalized therapies for individuals with "nano-rare" genetic forms of ALS and treat them for free, for life.
Topic
- March 30, 2022
Parkinson’s patients and their families are increasingly turning to genetic testing to learn more about their disease or risk of passing it on. But testing is complex, and counseling is advised.
Topic
- March 15, 2022
COVID patients who remain unresponsive after receiving respiratory support may require long time periods to regain consciousness; delays are related to blood oxygen levels.
Topic
- March 7, 2022
A newly discovered protein tangle has been associated with multiple neurodegenerative diseases and may have a role in causing the diseases.
Topic
- March 7, 2022
A one-hour time change may not seem like much but it causes health and sleep issues. Here's advice from Columbia doctors to minimize the effect.
Topic
- February 15, 2022
One of the cell's most common proteins may become too old and too stable in Alzheimer’s disease, altering neuronal activity and impairing memory.
Topic
- January 22, 2022
Based on Columbia research, an experimental drug for a rare type of ALS is being tested in a phase 3 clinical trial after a new study found that the drug lowered levels of a toxic protein.
Topic
- November 11, 2021
A study of more than 500 hospitalized COVID patients found that comorbidities do not necessarily result in the worst outcomes.
Topic
- November 1, 2021
Since 1955, “Merritt’s Neurology,” edited by Columbia neurologists, has been regarded as the standard reference work in the field. James Noble, MD, joins the ranks for the latest edition.
Topic
